SCHEMBL7079006

SCHEMBL7079006

Cc1nn(C)c2ncc(N(C=O)C(=O)Nc3cccc(Cl)c3)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
RAB9A P51151 5/20 0.45
NPC1 O15118 4/20 0.45
GAA P10253 1/20 0.45
HSP90AA1 P07900 1/20 0.43
NR3C1 P04150 4/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
CCR2 P41597 1/20 0.41
CCR5 P51681 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
SPR P35270 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7074009 0.90 NR3C1 (0.48) MEN1KMT2ARAB9ANPC1NR3C1
SCHEMBL7078063 0.88 SPR (0.40) RAB9ANPC1GAANR3C1MAPT
SCHEMBL7078734 0.87 POLB (0.41) NR3C1MAPTCCR2CCR5POLB
SCHEMBL7075366 0.87 PDE4A (0.49) MEN1KMT2ARAB9ANPC1NR3C1
SCHEMBL7137484 0.87 SPR (0.43) RAB9ANPC1NR3C1MAPTALDH1A1
SCHEMBL7081133 0.86 NR3C1 (0.44) MEN1KMT2ARAB9ANPC1NR3C1
SCHEMBL5961440 0.86 TP53 (0.47) MEN1KMT2ARAB9ANR3C1MAPT
SCHEMBL5961572 0.85 CCR2 (0.49) MEN1KMT2ANR3C1MAPTALDH1A1
SCHEMBL7079264 0.84 NR3C1 (0.40) NR3C1CCR2CCR5POLBSPR
SCHEMBL7077952 0.84 SPR (0.48) KMT2ARAB9ANR3C1CCR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670364-B2 For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases TELIK, INC. 2003-12-30 US claimed
US-20030096705-A1 Antagonists of MCP-1 function and methods of use thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2003-05-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096705-A1 Antagonists of MCP-1 function and methods of use thereof CCR2, CCR1, CCL2 MEN1 2137/4885KMT2A 4525/4885RAB9A 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.